A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors

This study has been completed.
Sponsor:
Information provided by:
Taiho Oncology, Inc.
ClinicalTrials.gov Identifier:
NCT00400023
First received: November 14, 2006
Last updated: April 7, 2011
Last verified: April 2011
  Purpose

This is a Phase 1, open-label, randomized, 2-sequence, cross-over, pharmacokinetic (PK) study evaluating the effect of the DPD inhibitory action of CDHP as an S-1 component compared with FT alone on the PK of 5-FU in patients with advanced solid tumors. The study will be conducted in 2 parts (Cross-Over Pharmacokinetic Phase and S-1 Extension Phase).


Condition Intervention Phase
Tumors
Drug: S-1
Drug: FT
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of the Dihydropyrimidine Dehydrogenase (Dpd) Inhibitory Action of 5-Chloro-2,4-Dihydroxypyridine (Cdhp) as an S-1 Component

Resource links provided by NLM:


Further study details as provided by Taiho Oncology, Inc.:

Primary Outcome Measures:
  • Cross-Over Pharmacokinetic Phase: To compare plasma concentrations, investigate the plasma and urine pharmacokinetic profiles, and to evaluate the duration of DPD inhibition after the administration of S-1 [ Time Frame: The Cross-Over Pharmacokinetic phase (Part 1) will last 11 days ] [ Designated as safety issue: No ]
  • S-1 Extension Phase: Efficacy (antitumor response) [ Time Frame: Each cycle of the S-1 Extension Phase (Part 2) will be 21 days (14 days S-1 treatment, 7 days recovery). The end of study for the Extension Phase will be 30 days after the last dose of S-1. ] [ Designated as safety issue: No ]
  • S-1 Extension Phase: Safety (Adverse events, lab assessments) [ Time Frame: Each cycle of the S-1 Extension Phase (Part 2) will be 21 days (14 days S-1 treatment, 7 days recovery). The end of study for the Extension Phase will be 30 days after the last dose of S-1. ] [ Designated as safety issue: Yes ]
  • S-1 Extension Phase: Pharmacokinetic profiles of the components of S-1 and their metabolites, and duration of DPD inhibition after administration of multiple doses (end of Cycle 1) [ Time Frame: Each cycle of the S-1 Extension Phase (Part 2) will be 21 days (14 days S-1 treatment, 7 days recovery). The end of study for the Extension Phase will be 30 days after the last dose of S-1. ] [ Designated as safety issue: No ]

Estimated Enrollment: 12
Study Start Date: September 2006
Study Completion Date: May 2007
Primary Completion Date: May 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1

During the Cross-Over Pharmacokinetic Phase, patients will be randomly assigned to receive one of the following treatment sequences:

  • Sequence A: Single dose of 50 mg S-1 (2 capsules of 25 mg) on Day 1 followed by a single dose of 800 mg FT (8 capsules of 100 mg) on Day 8
  • Sequence B: Single dose of 800 mg FT on Day 1 followed by a single dose of 50 mg S-1 on Day 8
Drug: S-1

During the Cross-Over PK Phase, S-1 will be administered as a 50 mg oral fixed dose and FT will be administered as an 800 mg oral fixed dose.

During the S-1 Extension Phase (Part 2), S-1 30 mg/m2 will be administered orally BID for 2 weeks (Day 1 through Day 14) followed by a 1-week recovery period (Day 15 through Day 21). This cycle will be repeated every 3 weeks.

Active Comparator: 2

During the Cross-Over Pharmacokinetic Phase, patients will be randomly assigned to receive one of the following treatment sequences:

  • Sequence A: Single dose of 50 mg S-1 (2 capsules of 25 mg) on Day 1 followed by a single dose of 800 mg FT (8 capsules of 100 mg) on Day 8
  • Sequence B: Single dose of 800 mg FT on Day 1 followed by a single dose of 50 mg S-1 on Day 8
Drug: FT
During the Cross-Over PK Phase, S-1 will be administered as a 50 mg oral fixed dose and FT will be administered as an 800 mg oral fixed dose.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

A patient must meet all of the following inclusion criteria to be eligible for enrollment in this study:

  1. Has histologically or cytologically proven advanced solid tumors for which no standard therapy exists.
  2. Has provided written informed consent.
  3. Is 18 years of age or older.
  4. Is able to take medications orally.
  5. Has Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2 (Appendix A, Performance Status).
  6. Has adequate organ function as defined by the following criteria:

    • Has transaminases AST (SGOT) and ALT (SGPT) ≤ 2.5 times the upper limit of normal (ULN). If liver function abnormalities are due to underlying malignancy, then AST (SGOT) and ALT (SGPT) may be ≤ 5 times ULN.
    • Has a total serum bilirubin ≤ 1.5 times ULN.
    • Has an absolute granulocyte count ≥ 1,500/mm3 (ie, ≥ 1.5 x 109/L by International Units [IU]).
    • Has a platelet count ≥ 100,000/mm3 (IU: ≥ 100 x 109/L).
    • Has a hemoglobin value of ≥ 9.0 g/dL.
    • Has a calculated creatinine clearance > 60 mL/min (by Cockcroft-Gault formula.76 See Appendix E).
  7. Is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

Exclude a patient from this study if he/she does not fulfill the inclusion criteria, or if any of the following conditions are observed:

  1. Has had treatment with any of the following within the specified time frame prior to study drug administration:

    • An investigational agent received either concurrently or within the last 30 days.
    • Previous therapy for malignancy within 21 days, including any chemotherapy, immunotherapy, biologic or hormonal therapy (6 weeks for nitrosureas or mitomycin C).
    • Previous radiotherapy within 14 days.
    • Current enrollment in another clinical study with an investigational agent. Patients participating in surveys or observational studies are eligible to participate in this study.
  2. Has a serious illness or medical condition(s) including, but not limited to, the following:

    • Myocardial infarction within the last 6 months, severe/unstable angina, congestive heart failure (New York Heart Association [NYHA] Class III or IV, see Appendix F).
    • Known (at the time of entry) gastrointestinal disorder, including malabsorption,chronic nausea, vomiting, or diarrhea present to the extent that it might interfere with oral intake and absorption of the study medication.
    • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the Investigator would make the patient inappropriate for entry into this study.
    • Known brain metastasis.
    • Known leptomeningeal metastasis.
    • Manifest ascites.
    • Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.
  3. Is receiving a concomitant treatment with drugs interacting with S-1 or FT. The following drugs are prohibited because there may be an interaction with S-1 or FT:

    • Sorivudine, uracil, dipyridamole, cimetidine and folinic acid (may enhance S-1 or FT activity).
    • Allopurinol (may diminish S-1 or FT activity).
    • Phenytoin (S-1 or FT may enhance phenytoin activity).
    • Flucytosine, a fluorinated pyrimidine antifungal agent (may enhance S-1 or FT, and flucytosine activity).
    • Pilocarpine (may inhibit CYP2A6 activity).
  4. Has sensitivity to 5-FU.
  5. Is a pregnant or lactating female.
  6. Is a patient with reproductive potential who refuses to use an adequate means of contraception (including male patients). 3.3.3 Discontinuation Criteria Clearly document the reason for the patient's discontinuation in the patient's source documents and on the CRF. Discontinue the patient from study if any of the following occur:

    • Patient withdraws consent.
    • Patient has toxicities that, in the opinion of the Investigator, require the patient's discontinuation.
    • Patient has an intercurrent illness that in the opinion of the Investigator requires the patient's discontinuation.
    • The Investigator concludes that it is in the patient's best interest to discontinue therapy.
    • Patient is willingly or inadvertently noncompliant in the opinion of the Investigator and requires the patient to be discontinued.
    • During optional Extension Phase, the patient has objective PD (defined by imaging studies or clinical evaluation). g. During optional Extension Phase, the patient requires a recovery period of > 4 weeks (ie, more than 3 weeks from the scheduled start date of the next cycle; see Section 4.5.4.1.1).
    • The patient completes the Cross-Over Pharmacokinetic Phase but does not choose to enter the optional S-1 Extension Phase.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00400023

Locations
United States, Arizona
Premiere Oncology of Arizona
Scottsdale, Arizona, United States, 85260
United States, California
Premiere Oncology, A Medical Corporation
Santa Monica, California, United States, 90404
United States, Connecticut
Yale Cancer Center
New Haven, Connecticut, United States, 06520
Sponsors and Collaborators
Taiho Oncology, Inc.
  More Information

No publications provided

Responsible Party: Peter Urrea/Senior VP Clinical and Regulatory Affairs, Taiho Pharma USA, Inc.
ClinicalTrials.gov Identifier: NCT00400023     History of Changes
Other Study ID Numbers: TPU-S1108
Study First Received: November 14, 2006
Last Updated: April 7, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Taiho Oncology, Inc.:
Advanced Solid Tumors

Additional relevant MeSH terms:
Dihydrouracil Dehydrogenase (NADP)
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 22, 2014